Ketogenic diet as a systems-level immunometabolic sensitization strategy in cancer therapy: integrating metabolism, immune reprogramming, microbiome dynamics, and epigenetic regulation
Medical Oncology · 2026
DOI: 10.1007/s12032-026-03425-0 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Medical Oncology, 2026. Verfasst von Muhammad Shaheer Mannan und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Marshfield Clinic, Marshfield, WI, USA. Hauptthemen laut MEDLINE: Diet, Ketogenic, Neoplasms, Epigenesis, Genetic, Gastrointestinal Microbiome. Die Arbeit nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical University of South Carolina.
Abstract (Originalsprache)
The ketogenic diet (KD) is increasingly being recognized as more than a simple metabolic intervention in cancer therapy. Emerging evidence suggests that KD may function as a systems-level immunometabolic sensitization strategy capable of enhancing therapeutic responsiveness through interconnected biologic mechanisms. Modern cancer therapies, including chemotherapy, targeted therapy, radiotherapy, and immunotherapy, are often limited by tumor adaptability and immune suppression. Tumors shift metabolism via the Warburg effect and fuel switching, promoting resistance under hypoxic and nutrient stress. KD is a high-fat and low-carb eating plan that increases ketone bodies such as β-hydroxybutyrate while lowering glucose availability. Under ketogenic conditions, cancer cells reduce glycolytic flux, while immune cells can oxidise ketones to sustain mitochondrial function and effector activity. KD also remodels the gut microbiome and induces epigenetic regulation through histone deacetylase inhibition. These combined effects may enhance chemotherapy, radiotherapy, targeted therapy, and immunotherapy by inducing metabolic stress, improving immune cell fitness, and altering tumour microenvironment signaling. Importantly, KD may function not as a standalone treatment but as a therapy-sensitization platform. However, current evidence remains preliminary and heterogeneous, and further mechanistic investigations and well-designed prospective clinical trials are necessary to determine optimal patient selection and long-term safety.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, Marshfield Clinic, Marshfield, WI, USA.
- Department of Internal Medicine, Medical University of South Carolina, Charleston, SC, USA. khanmuha@musc.edu.
- Ayub Medical College, Abbottabad, Pakistan.
Förderung
- Medical University of South Carolina
Zitieren
APA
Mannan, M. S., Khan, M. W., Haseeb Khan, M. A., Javed, A., Hussain, S. M., & Adil, H. (2026). Ketogenic diet as a systems-level immunometabolic sensitization strategy in cancer therapy: integrating metabolism, immune reprogramming, microbiome dynamics, and epigenetic regulation. Medical Oncology. https://doi.org/10.1007/s12032-026-03425-0
Vancouver
Mannan MS, Khan MW, Haseeb Khan MA, Javed A, Hussain SM, Adil H. Ketogenic diet as a systems-level immunometabolic sensitization strategy in cancer therapy: integrating metabolism, immune reprogramming, microbiome dynamics, and epigenetic regulation. Medical Oncology. 2026. doi:10.1007/s12032-026-03425-0
BibTeX
@article{Mannan2026,
author = {Mannan, Muhammad Shaheer and Khan, Muhammad Waqas and Haseeb Khan, Muhammad Abdul and Javed, Ahmed and Hussain, Syed Mujtaba and Adil, Hudda},
title = {Ketogenic diet as a systems-level immunometabolic sensitization strategy in cancer therapy: integrating metabolism, immune reprogramming, microbiome dynamics, and epigenetic regulation},
journal = {Medical Oncology},
year = {2026},
doi = {10.1007/s12032-026-03425-0}
}
EUVIMED